Related Experiment Videos
Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
S J Cryz1, J C Sadoff, E Fürer
1Swiss Serum and Vaccine Institute, Berne.
Insights
This study developed an octavalent Pseudomonas aeruginosa conjugate vaccine combining O-polysaccharide serotypes with toxin A. The vaccine proved safe, immunogenic, and protective against multiple P. aeruginosa strains.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Pseudomonas aeruginosa infections pose a significant threat, necessitating effective vaccines.
- Current vaccine strategies often target specific serotypes or virulence factors.
Purpose of the Study:
- To synthesize and evaluate an octavalent conjugate vaccine against Pseudomonas aeruginosa.
- To assess the safety, immunogenicity, and protective efficacy of the novel conjugate vaccine.
Main Methods:
- Conjugate vaccine synthesis by coupling O-polysaccharide (O-PS) from eight P. aeruginosa serotypes to detoxified toxin A using adipic acid dihydrazide spacer.
- Evaluation of vaccine toxicity, pyrogenicity, and antibody responses (IgG) against O-PS and toxin A in mice and guinea pigs.
- Assessment of vaccine efficacy through challenge studies with virulent P. aeruginosa strains.
Main Results:
- The octavalent conjugate vaccine was successfully synthesized, comprising 37% O-PS and 63% toxin A.
- The vaccine was non-toxic, non-pyrogenic, and induced significant IgG antibody levels against all included serotypes and toxin A.
- Specific serotypes (6, 10, 11) showed higher immunogenicity, while others (1, 5) had lower responses. Antitoxin A antibodies neutralized cytotoxicity.
- Immunization conferred significant protection against challenge with all vaccine-contained P. aeruginosa serotypes.
Conclusions:
- The developed octavalent Pseudomonas aeruginosa conjugate vaccine is safe and immunogenic.
- The vaccine demonstrates protective efficacy against multiple P. aeruginosa serotypes, highlighting its potential for clinical application.
- Further research is warranted to explore its full therapeutic potential.
Abstract:
An octavalent Pseudomonas aeruginosa conjugate vaccine was synthesized by covalently coupling the O-polysaccharide (O-PS) moiety derived from lipopolysaccharides of Habs serotypes 1, 2, 3, 4, 5, 6, 11 and 12 to toxin A. Adipic acid dihydrazide was used as a spacer molecule to facilitate conjugation. The vaccine was composed of 37% (w/w) O-PS and 63% toxin A, devoid of enzymatic activity characteristic of toxin A, non-toxic for mice and guinea pigs, and non-pyrogenic. The vaccine elicited a significant rise in immunoglobulin G antibody levels to all serotypes of lipopolysaccharide contained in the vaccine and to toxin A. Serotypes 6, 10 and 11 were most immunogenic in mice whereas serotypes 1 and 5 engendered the lowest antibody response. Antitoxin A antibody was able to neutralize the cytotoxicity of toxin A. Immunization of mice with the vaccine conferred significant protection against subsequent challenge with all P. aeruginosa serotype strains contained in the vaccine.